Our successful multi-year target identification collaboration with leading pharmaceutical company AstraZeneca tackles some of the world’s most complex diseases.
Our collaboration optimises target identification, combining our Knowledge Graph and AI drug discovery Platform with AstraZeneca’s data and disease expertise.
Our teams work side by side to uncover new insights into complex disease biology and predict novel targets that specifically treat the cause of that disease.
AstraZeneca has already selected a total of five targets to enter its portfolio, two in chronic kidney disease (CKD) and three in idiopathic pulmonary fibrosis (IPF).
The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca’s disease area expertise with BenevolentAI’s leading AI capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets.
Progress so far
Oct 6, 2022
May 17, 2022
Jan 13, 2022